Tia L. Bush Sells 11,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the sale, the chief technology officer now owns 121,503 shares of the company’s stock, valued at approximately $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded down $0.49 during midday trading on Tuesday, hitting $16.41. The company had a trading volume of 461,939 shares, compared to its average volume of 593,205. The firm has a fifty day simple moving average of $16.76 and a two-hundred day simple moving average of $15.22. Centessa Pharmaceuticals plc has a fifty-two week low of $7.38 and a fifty-two week high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -10.73 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC raised its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after acquiring an additional 1,116 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in Centessa Pharmaceuticals in the third quarter valued at about $187,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CNTA shares. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.